Editorial: glecaprevir/pibrentasvir for the treatment of hepatitis C virus-do baseline resistance-associated substitutions matter? Authors' reply

Aliment Pharmacol Ther. 2020 Apr;51(7):741. doi: 10.1111/apt.15666.

Authors

Achintya D Singh¹, Ramesh Kumar², Shalimar³

Affiliations

¹ Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
² Department of Gastroenterology, All India Institute of Medical Sciences, Patna, Bihar, India.
³ Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.

PMID: 32162375
DOI: 10.1111/apt.15666

No abstract available

Publication types

Editorial
Comment

MeSH terms

Aminoisobutyric Acids
Benzimidazoles
Cyclopropanes
Hepacivirus
Hepatitis C, Chronic*
Humans
Lactams, Macrocyclic
Leucine / analogs & derivatives
Proline / analogs & derivatives
Pyrrolidines
Quinoxalines
Sulfonamides

Substances

Aminoisobutyric Acids
Benzimidazoles
Cyclopropanes
Lactams, Macrocyclic
Pyrrolidines
Quinoxalines
Sulfonamides
pibrentasvir
Proline
Leucine
glecaprevir